A phase I study: safety of RG2077 (CTLA4-IgG4m) in patients with relapsing-remitting multiple sclerosis
Phase of Trial: Phase I
Latest Information Update: 30 Mar 2017
At a glance
- Drugs RG 2077 (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 20 May 2009 Additional lead investigator identified as reported by ClinicalTrials.gov.
- 08 Jun 2008 Status changed from in progress to completed, according to ClinicalTrials.gov
- 09 Oct 2005 New trial record.